Please use this identifier to cite or link to this item:
http://nopr.niscair.res.in/handle/123456789/1139| Title: | Recent thiazolidinediones as antidiabetics |
| Authors: | Imran, Mohd Ilyas, Babar Deepanjali Khan, Suroor Ahmad |
| Keywords: | Insulin sensitizing agents;Netoglitazone;Thiazolidinediones;Type 2 diabetes |
| Issue Date: | Feb-2007 |
| Publisher: | CSIR |
| Abstract: | Thiazolidinediones, a class of oral insulin sensitizing agents that improve insulin resistance, are agonists of peroxisome proliferator activated receptor-ϒ (PPAR-ϒ). Two clinically used drugs pioglitazone (ACTOS) and rosiglitazone (AVANDIA) have made a great contribution to therapy for type 2 diabetes. However, weight gain and hepatotoxicity are side effects of thiazolidinediones. For thiazolidinediones with lesser side effects, researchers are focusing on modification of side chain at C-5 of thiazolidinedione nucleus and its derivatization. Netoglitazone possesses both PPAR-⍺/ϒ dual agonistic activity. More thiazolidinedione derivatives like DRF-2189, PHT46, PMT13, DRF-2519 can be utilized as potent antidiabetic agents in future. |
| Page(s): | 99-109 |
| URI: | http://hdl.handle.net/123456789/1139 |
| ISSN: | 0022–4456 |
| Appears in Collections: | JSIR Vol.66(02) [February 2007] |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| JSIR 66(2) (2007) 99-109.pdf | 314.25 kB | Adobe PDF | View/Open |
Items in NOPR are protected by copyright, with all rights reserved, unless otherwise indicated.